↓ Skip to main content

Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance

Overview of attention for article published in Therapeutic Advances in Endocrinology and Metabolism, April 2015
Altmetric Badge

Mentioned by

facebook
2 Facebook pages

Readers on

mendeley
100 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Published in
Therapeutic Advances in Endocrinology and Metabolism, April 2015
DOI 10.1177/2042018815580257
Pubmed ID
Authors
Abstract

Glucagon-like polypeptide (GLP-1) receptor agonist treatment has multiple effects on glucose metabolism, supports the β cell, and promotes weight loss. There are now five GLP-1 agonists in clinical use with more in development. GLP-1 treatment typically can induce a lowering of hemoglobin A1c (HbA1c) of 0.5-1.5% over time with weight loss of 2-5%. In some individuals, a progressive loss of weight occurs. There is evidence that GLP-1 therapy opposes the loss of β cells which is a feature of type 2 diabetes. The chief downside of GLP-1 treatment is the gastrointestinal motility disturbance which is one of the modes of action of the hormone; significant nausea, vomiting, and diarrhea may lead to discontinuation of treatment. Although daily injection of GLP-1 agents is successful, the development of extended release preparations allows for injection once weekly, and perhaps much longer in the future. The indication for GLP-1 use is diabetes, but now, liraglutide has been approved for primary treatment of obesity. When oral agents fail to control glucose levels in type 2 diabetes, there is a choice between long-acting insulin and GLP-1 agonists as additional treatments. The lowering of HbA1c by either modality is equivalent in most studies. Patients lose weight with GLP-1 treatment and gain weight on insulin. There is a lower incidence of hypoglycemia with GLP-1 therapy but a much higher incidence of gastrointestinal complaints. Insulin dosing is flexible while GLP-1 agents have historically been administered at fixed dosages. Now, the use of combined long-acting insulin and GLP-1 agonists is promising a major therapeutic change. Combined therapy takes advantage of the benefits of both insulin and GLP-1 agents. Furthermore, direct admixture of both in the same syringe will permit flexible dosing, improvement of glucose levels, and reduction of both hypoglycemia and gastrointestinal side effects.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 100 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Colombia 1 1%
Brazil 1 1%
Unknown 98 98%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Master 16 16%
Researcher 12 12%
Student > Ph. D. Student 10 10%
Student > Bachelor 9 9%
Student > Postgraduate 8 8%
Other 20 20%
Unknown 25 25%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 37 37%
Pharmacology, Toxicology and Pharmaceutical Science 13 13%
Agricultural and Biological Sciences 4 4%
Unspecified 3 3%
Social Sciences 3 3%
Other 12 12%
Unknown 28 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 November 2015.
All research outputs
#18,420,033
of 22,818,766 outputs
Outputs from Therapeutic Advances in Endocrinology and Metabolism
#245
of 305 outputs
Outputs of similar age
#192,728
of 263,977 outputs
Outputs of similar age from Therapeutic Advances in Endocrinology and Metabolism
#3
of 4 outputs
Altmetric has tracked 22,818,766 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 305 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one is in the 3rd percentile – i.e., 3% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,977 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.